MRNA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Moderna is not a good buy right now for a beginner with a long-term horizon, even with $50,000-$100,000 to invest. The stock has strong momentum and supportive catalyst news, but it is already sharply extended after a huge run, and the current setup is overbought. For an impatient investor who does not want to wait for a better entry, I would not start a new position here. The better call is to hold off and wait for a more attractive pullback.
MRNA is in a strong bullish trend: price is above its key moving averages with SMA_5 > SMA_20 > SMA_200, and MACD histogram is positive and expanding, which confirms upward momentum. However, RSI_6 at 90.411 is deeply overbought, showing the move may be stretched in the near term. Price at 80.45 is above the pivot 68.425 and near resistance levels R1 77.554 and R2 83.195, so upside from here looks limited versus the risk of cooling off first. The recent pattern suggests short-term strength but poor entry quality today.
["FDA advisory committee gave unanimous support to Moderna's mRNA flu vaccine, improving the odds of approval by August 5.", "The company is expanding into cancer therapies and new disease areas, which supports the long-term growth story.", "Recent news highlights an in vivo CAR-T candidate, adding another potential pipeline catalyst.", "Congress trading data shows 1 purchase and no sales in the past 90 days, a positive signal from influential buyers.", "Analyst targets have generally moved higher over recent months, showing improving sentiment around the pipeline and Q1 results."]
["The stock has already surged nearly 150% over the past year, so much of the good news may already be priced in.", "RSI is extremely overbought, increasing the chance of near-term consolidation.", "Hedge funds are selling aggressively, with selling up 437.15% over the last quarter.", "Many growth catalysts, especially oncology and flu revenue upside, are still years away from meaningful commercialization.", "Financial risks from cash burn remain part of the long-term story."]
Latest quarter season: Q1. Moderna reported better-than-expected Q1 revenue of $389M and beat on both top and bottom lines. Analysts noted stronger international markets and improving financial discipline. The quarter looked solid operationally, but revenue growth still depends heavily on product uptake and future pipeline execution rather than already-established large recurring sales.
Analyst sentiment is mixed but improving. Recent target hikes came from Piper Sandler, UBS, Evercore ISI, RBC, Goldman Sachs, Morgan Stanley, and BofA, showing better expectations after Q1 and pipeline updates. However, the ratings are still split: Piper Sandler is Overweight, while Jefferies is Hold and BofA remains Underperform. Wall Street’s pros see improving pipeline momentum, regulatory wins, and long-term cancer vaccine potential; the cons are valuation uncertainty, revenue timing delays, and dependence on future clinical data. Overall, the Street is cautiously constructive but not uniformly bullish.
